Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20087392 | 0.85 | CA12 (0.53) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL22345342 | 0.81 | CA12 (0.36) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL18362362 | 0.77 | NR1D1 (0.33) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL2185396 | 0.77 | NR1D1 (0.35) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL6646724 | 0.75 | SIGMAR1 (0.33) | CA12CA14CA1CA7 | |
| Hydrochloric Acid SCHEMBL6840742 | 0.75 | NR1D1 (0.34) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL20087394 | 0.74 | AKT1 (0.36) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL8412077 | 0.74 | NR1D1 (0.34) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL19199788 | 0.73 | MEN1 (0.36) | CA12CA14CA1CA7NR1D1 | |
| SCHEMBL21548073 | 0.71 | NR1D1 (0.33) | NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | CA12 4126/4885CA14 4430/4885CA1 3168/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | CA12 4126/4885CA14 4430/4885CA1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.